Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Non-Current Assets (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Non-Current Assets for 6 consecutive years, with $71.6 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 8.69% to $71.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $300.9 million through Dec 2025, down 0.94% year-over-year, with the annual reading at $71.6 million for FY2025, 8.69% down from the prior year.
  • Non-Current Assets for Q4 2025 was $71.6 million at TScan Therapeutics, down from $74.1 million in the prior quarter.
  • The five-year high for Non-Current Assets was $78.4 million in Q4 2024, with the low at $17.9 million in Q3 2021.
  • Average Non-Current Assets over 5 years is $58.4 million, with a median of $73.9 million recorded in 2024.
  • The sharpest move saw Non-Current Assets soared 233.87% in 2022, then dropped 8.69% in 2025.
  • Over 5 years, Non-Current Assets stood at $22.5 million in 2021, then skyrocketed by 233.87% to $75.0 million in 2022, then grew by 3.93% to $77.9 million in 2023, then grew by 0.62% to $78.4 million in 2024, then fell by 8.69% to $71.6 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $71.6 million, $74.1 million, and $77.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.